Search This Blog

Tuesday, May 3, 2016

FDA Grants Priority Review For Amgen's Supplemental Biologics License Application For BLINCYTO® (Blinatumomab)

Acceptance Reinforces Significant Unmet Need for Difficult-to-Treat Type of Pediatric Acute Lymphoblastic Leukemia



Amgen - Investors - RSS Content

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.